Kivanc birsoy - Related publications

Affiliations: 
Whitehead Institute, Cambridge, MA, United States 
NOTE: We are testing a new system for identifying relevant work based on semantic analysis that identifies similarities between recently published papers and the current author's publications. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches.
18 most relevant papers in past 60 days:
Year Citation  Score
2022 Liu XZ, Rulina A, Choi MH, Pedersen L, Lepland J, Takle ST, Madeleine N, Peters SD, Wogsland CE, Grøndal SM, Lorens JB, Goodarzi H, Lønning PE, Knappskog S, Molven A, et al. C/EBPB-dependent adaptation to palmitic acid promotes tumor formation in hormone receptor negative breast cancer. Nature Communications. 13: 69. PMID 35013251 DOI: 10.1038/s41467-021-27734-2   
2022 Bolatkan A, Asada K, Kaneko S, Suvarna K, Ikawa N, Machino H, Komatsu M, Shiina S, Hamamoto R. Downregulation of METTL6 mitigates cell progression, migration, invasion and adhesion in hepatocellular carcinoma by inhibiting cell adhesion molecules. International Journal of Oncology. 60. PMID 34913069 DOI: 10.3892/ijo.2021.5294   
2022 Silva C, Andrade N, Guimarães JT, Cardoso E, Meireles C, Pinto V, Paiva J, Martel F. The pro-proliferative effect of insulin in human breast epithelial DMBA-transformed and non-transformed cell lines is PI3K-, mTOR- and GLUT1-dependent. Cell Biochemistry and Function. PMID 35014047 DOI: 10.1002/cbf.3681   
2022 Chen P, Hu J, Han X, Chen Y. Advances in the functional roles of N6-methyladenosine modification in cancer progression: mechanisms and clinical implications. Molecular Biology Reports. PMID 35025029 DOI: 10.1007/s11033-022-07126-5   
2022 Zhou Y, Guo Y, Tam KY. Targeting glucose metabolism to develop anticancer treatments and therapeutic patents. Expert Opinion On Therapeutic Patents. PMID 35001793 DOI: 10.1080/13543776.2022.2027912   
2022 Wang D, Sun L, Okuda S, Yamamoto D, Nakayama M, Oshima H, Saito H, Kouyama Y, Mimori K, Ando T, Watanabe S, Oshima M. Nano-scale physical properties characteristic to metastatic intestinal cancer cells identified by high-speed scanning ion conductance microscope. Biomaterials. 280: 121256. PMID 34794825 DOI: 10.1016/j.biomaterials.2021.121256   
2022 Yin L, Zhang Y, Zheng L. Analysis of differentially expressed long non‑coding RNAs revealed a pro‑tumor role of MIR205HG in cervical cancer. Molecular Medicine Reports. 25. PMID 34878159 DOI: 10.3892/mmr.2021.12558   
2022 Xie XP, Laks DR, Sun D, Ganbold M, Wang Z, Pedraza AM, Bale T, Tabar V, Brennan C, Zhou X, Parada LF. Quiescent human glioblastoma cancer stem cells drive tumor initiation, expansion, and recurrence following chemotherapy. Developmental Cell. 57: 32-46.e8. PMID 35016005 DOI: 10.1016/j.devcel.2021.12.007   
2022 Xie G, Peng Z, Liang J, Larabee SM, Drachenberg CB, Yfantis H, Raufman JP. Zinc finger protein 277 is an intestinal transit-amplifying cell marker and colon cancer oncogene. Jci Insight. PMID 35015732 DOI: 10.1172/jci.insight.150894   
2022 Li B, Xiao Q, Shan L, Song Y. NCAPH promotes cell proliferation and inhibits cell apoptosis of bladder cancer cells through MEK/ERK signaling pathway. Cell Cycle (Georgetown, Tex.). 1-12. PMID 34974790 DOI: 10.1080/15384101.2021.2021050   
2022 Qin D, Ni C, Tan B, Huang S, Deng B, Huang Z. LINC01207 promotes prostate cancer progression by sponging miR-1182 to upregulate AKT3. Oncology Letters. 23: 57. PMID 34992689 DOI: 10.3892/ol.2021.13175   
2022 Fang F, Yuan Q. Anlotinib inhibits the proliferation, migration and invasion, and induces apoptosis of breast cancer cells by downregulating TFAP2C. Oncology Letters. 23: 46. PMID 34976158 DOI: 10.3892/ol.2021.13164   
2022 Salvi A, Young AN, Huntsman AC, Pergande MR, Korkmaz MA, Rathnayake RA, Mize BK, Kinghorn AD, Zhang X, Ratia K, Schirle M, Thomas JR, Brittain SM, Shelton C, Aldrich LN, et al. PHY34 inhibits autophagy through V-ATPase V0A2 subunit inhibition and CAS/CSE1L nuclear cargo trafficking in high grade serous ovarian cancer. Cell Death & Disease. 13: 45. PMID 35013112 DOI: 10.1038/s41419-021-04495-w   
2022 Guo T, Zhang Z, Zhu L, Chen W, Ding Y, Li W, Huang Y, Huang J, Pan X. TRIM55 suppresses malignant biological behavior of lung adenocarcinoma cells by increasing protein degradation of Snail1. Cancer Biology & Therapy. 1-10. PMID 34974792 DOI: 10.1080/15384047.2021.2004835   
2022 Inaishi T, Shibata M, Ichikawa T, Kanda M, Hayashi M, Soeda I, Takeuchi D, Takano Y, Tsunoda N, Kodera Y, Kikumori T. Platelet isoform of phosphofructokinase accelerates malignant features in breast cancer. Oncology Reports. 47. PMID 34751415 DOI: 10.3892/or.2021.8220   
2022 Sun Y, Tian Y, He J, Tian Y, Zhang G, Zhao R, Zhu WJ, Gao P. Linc01133 contributes to gastric cancer growth by enhancing YES1-dependent YAP1 nuclear translocation via sponging miR-145-5p. Cell Death & Disease. 13: 51. PMID 35017464 DOI: 10.1038/s41419-022-04500-w   
2022 Li L, Hu Y, Chen D, Zhu J, Bao W, Xu X, Chen H, Chen W, Feng R. CMTM5 inhibits the development of prostate cancer via the EGFR/PI3K/AKT signaling pathway. Molecular Medicine Reports. 25. PMID 34791506 DOI: 10.3892/mmr.2021.12533   
2022 Weiss F, Lauffenburger D, Friedl P. Towards targeting of shared mechanisms of cancer metastasis and therapy resistance. Nature Reviews. Cancer. PMID 35013601 DOI: 10.1038/s41568-021-00427-0